ASTHMA: New Phase III data show tiotropium* Respimat® effective across asthma severities
- Significant unmet medical need in patients with asthma who continue to experience symptoms despite current standard treatments
- Improved understanding of tiotropium Respimat® as add-on treatment for patients with different severities of asthma
- Results add to existing evidence of efficacy and safety of tiotropium Respimat® in patients who remained symptomatic despite treatment with at least ICS†/LABA‡
- 2014 AAAAI Annual Meeting
Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities. These data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2014 annual meeting in San Diego.
“Even with current treatment options, at least 40 percent of patients with asthma remain symptomatic,[1] which may put them at greater risk for exacerbations or asthma worsening" said Professor Pierluigi Paggiaro, Professor of Respiratory Medicine, University of Pisa, and lead author on the GraziaTinA-asthma® study. “It is important to investigate the efficacy and safety of new treatment options across different asthma severities.”
The first results from the Phase III GraziaTinA-asthma® study were announced. The study demonstrated that tiotropium Respimat® improved lung function and was well tolerated in patients with asthma who remain symptomatic while receiving low-dose maintenance ICS treatment.[2]
Also presented at the meeting was a new subset of data from the Phase III MezzoTinA-asthma® trials. The data showed that in patients with asthma who remained symptomatic while receiving moderate-dose maintenance ICS therapy, the addition of once-daily tiotropium reduced airflow obstruction independent of allergic status, as measured by the TH2 phenotype biomarker.[3]
Finally, an analysis of a subset from the Phase III PrimoTinA-asthma® trials found the addition of once-daily tiotropium improved lung function responses independently of concomitant use of a leukotriene receptor antagonist (LTRA). This effect was demonstrated in patients with asthma who remained symptomatic despite receiving treatment with at least ICS/LABA.[4] Previous results from these pivotal, PrimoTinA-asthma® trials have shown that the addition of tiotropium Respimat® significantly increased time to first severe asthma exacerbation, as well as time to first episode of asthma worsening, compared with at least ICS/LABA therapy alone (current standard therapy).[5]
NewsHome: An innovative resource for journalists
The Boehringer Ingelheim respiratory www.NewsHome.com is available and is the one-stop-shop for clear, concise and easy to understand information about asthma and other respiratory illnesses for the media.
For more detailed information please follow the links below:
About tiotropium Respimat® in asthma factsheet: http://bit.ly/NqNjfv
To access the full abstracts please follow the link: http://bit.ly/1jh3AyF
To view the ‘notes to editors’ and ‘references’: http://bit.ly/1cUhMfl
* Please note: Tiotropium Respimat® is currently NOT APPROVED for use in asthma, except in Colombia. Tiotropium’s safety and efficacy have not yet been fully established in asthma.
†Inhaled corticosteroid
‡Long-acting beta2-agonists
Website: http://www.boehringer-ingelheim.com
Contact
Boehringer Ingelheim
Linda Calandra
+49 6132 77 3519
linda.calandra@boehringer-ingelheim.com
More information
www.boehringer-ingelheim.com
This news is a press release provided by Boehringer Ingelheim International GmbH. Korea Newswire follows these editorial guidelines.
-
2021년 9월 10일 15:15
-
2021년 3월 2일 15:05